What is Mounjaro? A Complete UK Guide

Mounjaro is the brand name for tirzepatide, a prescription-only injectable medication manufactured by Eli Lilly. Originally developed to treat type 2 diabetes, it has become one of the most effective weight management treatments available in the UK. Mounjaro is administered once weekly via a pre-filled pen (KwikPen) and is available in six doses: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg. It was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in the UK and has since gained widespread attention for its significant weight loss results.

Mounjaro is a dual GIP and GLP-1 receptor agonist, meaning it mimics two natural gut hormones at the same time. GLP-1 (glucagon-like peptide-1) slows gastric emptying, reduces appetite, and improves blood sugar control. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1 to further enhance insulin secretion and influence fat metabolism. This dual mechanism is what sets Mounjaro apart from single-agonist treatments like semaglutide (Wegovy, Ozempic). By targeting two pathways instead of one, tirzepatide produces greater appetite suppression and, in clinical trials, greater overall weight loss. Your body naturally produces both GIP and GLP-1 after eating. Mounjaro essentially amplifies these signals, making you feel full sooner and for longer after meals.

In the UK, Mounjaro is prescribed for weight management in adults who meet specific criteria. Most private prescribers require a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea. It is not suitable for everyone. Mounjaro should not be used during pregnancy, by people with a personal or family history of medullary thyroid carcinoma, or by those with multiple endocrine neoplasia syndrome type 2 (MEN 2). Your prescriber will assess your full medical history during the consultation process before issuing a prescription. Mounjaro is intended to be used alongside a reduced-calorie diet and increased physical activity, not as a standalone treatment.

The clinical evidence for Mounjaro is strong. The SURMOUNT clinical trial programme, which includes SURMOUNT-1 through SURMOUNT-4, studied tirzepatide across thousands of participants. In SURMOUNT-1, participants taking the highest dose (15mg) lost an average of 22.5% of their body weight over 72 weeks, compared to 2.4% for the placebo group. Even at the lower 5mg dose, participants achieved around 15% weight loss. SURMOUNT-2 focused on people with type 2 diabetes and obesity, showing an average weight reduction of 14.7% at the highest dose. SURMOUNT-3 and SURMOUNT-4 examined long-term maintenance and showed that continued treatment helped sustain weight loss results. These are among the highest weight loss figures seen in any clinical trial for an anti-obesity medication. However, individual results vary and depend on factors like dose, diet, exercise, and adherence to treatment.

Semaglutide (sold as Wegovy for weight loss and Ozempic for diabetes) is a GLP-1 receptor agonist that targets one gut hormone. Mounjaro targets two: GIP and GLP-1. In head-to-head clinical comparisons, tirzepatide has consistently produced greater average weight loss than semaglutide. While Wegovy typically achieves around 15% body weight reduction, Mounjaro has shown results closer to 20-22% at higher doses. Both medications are injectable, taken once weekly, and share similar side effect profiles centred on gastrointestinal symptoms. The choice between them should be made with your prescriber based on your individual health profile, tolerance, and treatment goals.

Mounjaro is a prescription-only medicine (POM) in the UK. It is currently available on the NHS for type 2 diabetes management but is not yet routinely prescribed on the NHS for weight management alone. Most people access Mounjaro for weight loss through private online pharmacies. The process typically involves completing an online health questionnaire, having your details reviewed by a registered prescriber (doctor or pharmacist prescriber), and receiving the medication by post with cold-chain delivery. Prices range from around £149 to £299 per month depending on the dose and pharmacy. Always ensure your pharmacy is registered with the General Pharmaceutical Council (GPhC) and that a genuine clinical consultation is included.